Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab for corticosteroid-resistant idiopathic IgA nephropathy flares
2024-512154-24-00Phase 4Completed
- Sponsor
- IRBLleida
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ravulizumab in IgA nephropathy (IgAN), sponsored by IRBLleida. Primary endpoint: Reduction of proteinuria and hematuria at Week 26. Started May 2023; status: completed.
02
Drugs
ravulizumab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2024-512154-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512154-24-00.